Posts Tagged ‘USPTO examiner’

Fifty Ways To Leave Your Lover And Nine Ways To Attack Patents

Tuesday, September 13th, 2011

As a “quick guide” to the Patent Reform Bill, H.R. 1249, that will soon become law, these are the sections of the Act and of the present statute that will all be, or remain effective, upon enactment, to facilitate blocking the issuance of applications or cancellation of objectionable claims. I will try to be brief, but it is not easy. Section references are to section of the Bill; “s.” references are to sections of 35 U.S.C.

1.  Sec. 3: Derivation proceedings (This replaces s. 291 – Interfering patents)

2.  Sec. 6: Citation of prior art and written statements  (Modifies s. 301 – Citation of prior art in an issued patent).

3.  S. 302-307 – “Old” ex parte reexamination is not affected by Bill. (But, remember, ex parte reexamination is essentially unused now.)

4.  S. 251-253. Reissue section is unscathed.

5.  Sec. 6: Inter partes review (Substantially modifies inter partes reexamination – must wait to file until after “opposition period” for post-grant review).

6.  Sec. 6: s. 321: Post-grant review (This is the new “opposition” section – must be filed within 9 mos. of issuance.)

7.   Sec. 8: Adds s. 122(e)   to permit preissuance submissions of art by third parties.

8.  Sec. 12: Adds s. 257: “Supplemental examination to consider, reconsider, or correct information.” Commentators have noted that these proceedings will permit patent owners to purge “fraud,” but there are exceptions.

9.   Sec. 18: Transitional post-grant review proceeding  for review of validity of business method patents – Can be initiated by defendant in civil suit.

Since reissue, ex parte reexamination, and supplemental examination are owner-initiated, perhaps I should have titled this post, “Nine Ways to Limit Patent Protection”, but then I would have had to list sections involving limiting false marking suits and  the ban on patenting human organisms.  I hope that this will help you locate specific parts of the Bill and of 35 USC as the commentary begins to pile up. As Prof. Hal Wegner summarizes this array:

“A major feature of the [Bill] is the creation of a variety of new post-grant review procedures. The difficulty with both the current and the new procedures results in part from the fact that essentially nothing is being  taken away while time consuming procedures are added to the burden of the upper end professionals at the Patent Office, all at a time when the Board is slowly sinking into an ever greater backlog.” (H.C. Wegner, The 2011 Patent Law: Law and Practice, Version 5.0, Sept. 8, 2011).

Hear! Hear! And, by the way, the Patent Office Board of Appeals and Interferences  is now “The Patent Trial and Appeal Board.” Check out its duties at Section 6 of the Bill.

Microsoft V. i4i – Prosecution And The “Variable Proof Regime”

Friday, March 25th, 2011

The Government recently weighed in on this important appeal with its amicus brief, signed by Neal Katyal, Acting Solicitor General. (A copy can be found at the end of this post.) The question posed is simply: “Whether, when the defendant [here Petitioner i4i] in an infringement suit asserts as a defense that the relevant patent is invalid, the defendant must prove invalidity by clear and convincing evidence.”

The major portion of the brief argues “clearly and convincingly” that both precedent and legislative history compel a finding that the clear and convincing (C&C) standard is the appropriate burden of proof for the defendant to meet, even when the defendant introduces evidence of invalidity that was not before the PTO during the examination process – even though the new evidence may “carry more weight and go further toward sustaining the attacker’s unchanging burden.” American Hoist & Derrick Co., 725 F.2d 1350, 1360 (Fed. Cir. 1984).

(more…)

Defining the Abstract and Conceptual – USPTO Issues “Guidance” Post-Bilski

Monday, August 2nd, 2010

Before I write another word, I want to recognize and applaud the intellectual and logistical effort it must have taken for Director Kappos and his helpers to put together six pages of “Interim Guidance For Determining Subject Matter Eligibility for Process Claims in View of Bilski v. Kappos,” 75 Fed. Reg. 43922 (July 27, 2010), (attached at end of post) “for its personnel to use when determining subject matter eligibility under U.S.C 101…The Office is especially interested in receiving comments regarding the scope and extent of the holding in Bilski.” The Office deserves our attention.

In my last post, I considered the difficulty in setting standards by which to determine whether or not a claim to a process is an abstract idea or rather does it involve concrete technology. The Interim Guidance (an official “Notice”) tackles this question head on. The Notice cites Chakrabarty as endorsing an expansive view of what constitutes a “new and useful process,” limited by the exceptions “laws of nature, physical phenomena and abstract ideas.” The Notice observes that “the Office had used the ‘abstract idea’ exception in cases where a claimed ‘method’ did not sufficiently recite a physical instantiation…Thus, the Bilski claims were said to be drawn to an ‘abstract idea’ despite the fact that they included steps of initiating transactions. The ‘abstractness’ is in the sense that there are no limitations as to the mechanism for entering into the transactions.” Notice at 93924. (Such limitations create the instantiation, a word I had to look up.)

The Notice discusses, and goes on to outline, four primary factors weighing toward patent eligibility and four primary factors weighing against it. The first step in the “pro” column is the express or inherent recitation of a machine or transformation. Likewise, the first and second “con” steps are no, or insufficient recitation, of a machine or transformation (again, express or inherent). Then it gets interesting. Factor three of the “pro” list is that the claim is directed toward a practical application of a law of nature, that limits the execution of the steps. The “con” factor is that the claim is not directed to the application of a law of nature and would monopolize a natural force or patent a scientific fact. A “con” example might be a claim, not to a diagnostic assay for a vitamin deficiency or cancer, but to the underlying fact that human blood contains certain amounts of homocysteine or PSA.

The fourth “pro” factor begins to cross into even less intellectually stable realms: “The claim is more than a mere statement of a concept.” The “con” factor mirrors it, “The claim is a mere statement of a general concept…use of the concept, as expressed in the method would effectively grant a monopoly over the concept.” But on reflection, these are more practical factors then they might first appear. Every prep/pros practitioner has encountered inventors who want to patent concepts or bright ideas, as opposed to inventions. Such a general concept might be stated as correlating mutations in genes to a propensity to develop cancer. How about “A car that runs on water as fuel.” I once had a professor approach me to patent his idea to develop a pig with organs that would not give rise to a rejection response when transplanted into humans. This was indeed a bright idea, but he had no idea how to create such a pig. This sort of “invention” was so common in the early days of biotechnology, that I wrote in the margins of my copy of Chemical Patent Practice (J. L. White): “You don’t patent ‘concepts’, you patent inventions; e.g., ‘power transfer’ vs. the gears that do it.” BNA PCTJ vol. 34, 264 (1987); Perkin-Elmer Corp. v Westinghouse Electric Corp.” I will leave it to you to check the cites.


bilski_guidance_27jul2010

Director Kappos Kills Prosecution Regulations Package

Thursday, October 8th, 2009

Two years of fear and loathing have ended, as the USPTO has announced that it is rescinding the “Continuations” and “Claims” rules that have been hanging over the heads of practitioners, and will move to dismiss/vacate the pending lawsuit over the rules. Like a legal sword of Damocles, there was always the chance that the rules would drop into place and cut-off our ability to prosecute patent families to completion. Remember, earlier this year the Federal Circuit gave the PTO permission to implement all but the rule limiting continuations. As an attorney who felt forced to begin to compress claim sets in pending applications near the eve of the rules going into force in 2007, the potential financial hardships to small pharma/biotech companies attempting to protect nascent technologies in a step-wise fashion was manifest. And did it ever make sense, at a time when PTO filings were dropping off, to implement rules that would further reduce filings? (One senior Examiner/union rep told me that opposition among the Examiners was almost universal.) Luckily, Glaxo and Dr. Tafas had the nerve to challenge the right of the PTO to promulgate such rules. They didn’t win it all in court, but bought us all time for a new Administration and blessed restraint.

USPTO Press Release.pdf